Tilray Brands (TLRY) Other Non-Current Liabilities (2019 - 2026)
Tilray Brands' (TLRY) quarterly Other Non-Current Liabilities came in at $4.4 million in Q2 2026, down 70.67% YoY from $15.0 million in Q2 2025, and up 2582.93% on a QoQ basis from $164000.0 in Q1 2026.
Tilray Brands (TLRY) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 8 years of Other Non-Current Liabilities data on file, last reported at $4.4 million in Q2 2026.
- Quarterly Other Non-Current Liabilities fell 70.67% year-over-year to $4.4 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.4 million (down 70.67% YoY) and the FY2026 annual result came in at $4.4 million, down 70.67% from the prior year.
- Other Non-Current Liabilities grew to $4.4 million in Q2 2026, from $164000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $15.0 million in Q2 2025 to a low of $17000.0 in Q4 2024.
- A 5-year average of $5.2 million and a median of $354500.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities plunged 99.87% — and 2025, when it soared 16566.67%.
- Tracing TLRY's Other Non-Current Liabilities over 5 years: stood at $185000.0 in 2022, then soared by 6927.03% to $13.0 million in 2023, then sank by 99.87% to $17000.0 in 2024, then soared by 2352.94% to $417000.0 in 2025, then soared by 955.16% to $4.4 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $4.4 million (Q2 2026), $164000.0 (Q1 2026), and $417000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 4.40 Mn |
| Feb 28, 2026 | 164,000.00 |
| Nov 30, 2025 | 417,000.00 |
| May 31, 2025 | 15.00 Mn |
| Nov 30, 2024 | 17,000.00 |
| Aug 31, 2024 | 99,000.00 |
| May 31, 2024 | 90,000.00 |
| Feb 29, 2024 | 14.00 Mn |
| Nov 30, 2023 | 13.00 Mn |
| Aug 31, 2023 | 13.00 Mn |
| May 31, 2023 | 10.89 Mn |
| Feb 28, 2023 | 10.60 Mn |
| Nov 30, 2022 | 185,000.00 |
| Aug 31, 2022 | 179,000.00 |
| May 31, 2022 | 191,000.00 |
| Feb 28, 2022 | 292,000.00 |
| Nov 30, 2021 | 320,000.00 |
| Aug 31, 2021 | 4.51 Mn |
| May 31, 2021 | 3.91 Mn |
| Mar 31, 2020 | 5.42 Mn |